Comment on Ågren et al. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes care

Diabetes Care

Volumn 37, Issue 11, 2014, Pages e243-

  Rijken, Dingeman C ^a   De Willige, Shirley Uitte ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 13A; CALCIUM; FIBRIN; THROMBIN; UREA; ALPHA 2 ANTIPLASMIN;

BLOOD CLOT LYSIS; CROSS LINKING; DISEASE ASSOCIATION; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN CLOT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NOTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; COMPLICATION; FEMALE; MALE; METABOLISM;

ALPHA-2-ANTIPLASMIN; DIABETES MELLITUS, TYPE 1; FEMALE; FIBRIN; HUMANS; MALE;

EID: 84910118583     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1336     Document Type: Note

References (5)

1. Agren A, Jörneskog G, Elgue G, Henriksson P, Wallen H, Wiman B. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care 2014;37:2007-2014
2. Lorand L. Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost 2005;3:1337-1348
3. 2-antiplasminbinding sites. Biochemistry 2010;49:7643-7651
4. Talens S, Leebeek FW, Demmers JA, Rijken DC. Identification of fibrin clot-bound plasma proteins. PLoS One 2012;7:e41966
5. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980;65:290-297